Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Navigo Proteins Enters R&D Collaboration with SCK CEN

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Navigo Proteins Enters R&D Collaboration with SCK CEN for Targeted Radiotheranostics

This partnership will focus on the preclinical development of next-generation radiotheranostics, using the Auger-electron emitting radioisotope Terbium.

By: Rachel Klemovitch

Assistant Editor

Navigo Proteins GmbH announced a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, that will focus on the preclinical development of next-generation radiotheranostics, using the Auger-electron emitting radioisotope Terbium (161Tb).

The partnership will leverage Navigo Proteins’ Affilin and HEAD platforms and knowledge of radiotheranostic development with SCK CEN’s expertise in radioisotopes. The two organizations aim to accelerate the development of radioligand therapies—highly specific, targeted therapies for cancer patients.

The collaboration will focus on preclinical studies of multiple undisclosed targets using radiotheranostic approaches. Researchers will test these molecules to deliver the radioactivity to tumors and assess their efficiency. The aim is to identify a candidate within two to three years and prepare all necessary data to initiate clinical studies.

“Navigo Proteins and SCK CEN each have extensive experience in key ingredients of radiopharmaceuticals. Navigo has developed carrier molecules, while SCK CEN provides terbium-161, infrastructure, and expertise in preclinical testing. Combining these complementary strengths saves valuable development time,” commented, Koen Hasaers, Director of Nuclear Medical Applications at SCK CEN.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics